ZANUBRUTINIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H29N5O3
Molecular Weight	471.5509
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of ZANUBRUTINIB

Structure Search

SMILES

NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4

InChI

InChIKey=RNOAOAWBMHREKO-QFIPXVFZSA-N

InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C27H29N5O3
Molecular Weight	471.5509
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:53:49 UTC 2023` Edited by `admin` on `Sat Dec 16 10:53:49 UTC 2023`
Record UNII	AG9MHG098Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZANUBRUTINIB

Official Name

English

PYRAZOLO(1,5-A)PYRIMIDINE-3-CARBOXAMIDE, 4,5,6,7-TETRAHYDRO-7-(1-(1-OXO-2-PROPEN-1-YL)-4-PIPERIDINYL)-2-(4-PHENOXYPHENYL)-, (7S)-

Systematic Name

English

ZANUBRUTINIB [USAN]

Common Name

English

BRUKINSA

Brand Name

English

BGB-3111

Code

English

(7S)-2-(4-Phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide

Systematic Name

English

ZANUBRUTINIB [MI]

Common Name

English

ZANUBRUTINIB [ORANGE BOOK]

Common Name

English

Zanubrutinib [WHO-DD]

Common Name

English

zanubrutinib [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

757020

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

FDA ORPHAN DRUG

889422

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

EU-Orphan Drug

EU/3/19/2167

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

FDA ORPHAN DRUG

757120

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

NCI_THESAURUS

C124801

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

FDA ORPHAN DRUG

527616

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

NCI_THESAURUS

C129825

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

FDA ORPHAN DRUG

527516

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

FDA ORPHAN DRUG

527416

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

FDA ORPHAN DRUG

756920

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

Code System Code Type Description

CAS

1691249-45-2

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

DAILYMED

AG9MHG098Z

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

RXCUI

2262435

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

NCI_THESAURUS

C141428

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

WIKIPEDIA

Zanubrutinib

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

EPA CompTox

DTXSID701026208

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

DRUG BANK

DB15035

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

DRUG CENTRAL

5353

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

PUBCHEM

135565884

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

CAS

1651179-04-2

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

NO STRUCTURE GIVEN

FDA UNII

AG9MHG098Z

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

INN

10555

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

MERCK INDEX

m12172

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

EVMPD

SUB195236

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

USAN

FG-152

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

SMS_ID

100000181509

Created by admin on Sat Dec 16 10:53:50 UTC 2023 , Edited by admin on Sat Dec 16 10:53:50 UTC 2023

PRIMARY

Related Record Type Details


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INDUCER

Comments:

Zanubrutinib is a weak inducer of CYP3A4 and CYP2C19 in vivo.

Interaction Type:

WEAK


					AG9MHG098Z

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

Zanubrutinib is approximately 94.2% bound to human plasma proteins in vitro, independent of concentration.

Interaction Type:

BINDING

Amount:


					AG9MHG098Z

EXCRETED UNCHANGED

Qualification:

FECAL

Amount:


					0UY97CSG1T

CYTOCHROME P450 2B6

METABOLIC ENZYME -> INDUCER

Comments:

Zanubrutinib induces CYP2B6 in vitro.


					SBH6S6T2J2

TYROSINE-PROTEIN KINASE BTK

TARGET -> INHIBITOR

Interaction Type:

IRREVERSIBLE INHIBITOR


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR


					081I12ZA58

CYTOCHROME P450 2C19

METABOLIC ENZYME -> INDUCER

Comments:

Zanubrutinib is a weak inducer of CYP3A4 and CYP2C19 in vivo.

Interaction Type:

WEAK

Related Record Type Details


					JA5TK72ZJ2

4,5,6,7-Tetrahydro-2-(4-phenoxyphenyl)-7-(4-piperidinyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile

IMPURITY -> PARENT

Amount:


					PNF3XEA9TH

tert-Butyl 4-[3-carbamoyl-2-(4-phenoxyphenyl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidin-7-yl]piperidine-1-carboxylate

IMPURITY -> PARENT

Amount:


					Q86GGJ4M7G

tert-Butyl 2-[(2E)-3-(dimethylamino)prop-2-enoyl]piperidine-1-carboxylate

IMPURITY -> PARENT

Amount:

Related Record Type Details


					AG9MHG098Z

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
blood-to-plasma ratio	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION

Volume of Distribution	PHARMACOKINETIC